Ads
related to: nintedanib for ipf 1 8- How It Helps
Discover How OFEV®
May Help Patients
- Why OFEV®?
Ask Your Doctor If OFEV®
A Treatment For You
- Caregiver Guide
Find Out How To Help.
Resources For Caregivers
- Caregiver Information
Find Supportive Resources
For Caregivers
- How It Helps
Search results
Results from the WOW.Com Content Network
Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer. [5]
Idiopathic pulmonary fibrosis; Other names: Fibrosing alveolitis, cryptogenic fibrosing alveolitis, diffuse fibrosing alveolitis, usual interstitial pneumonitis, diffuse interstitial pneumonitis: Figure A shows the location of the lungs and airways in the body. The inset image shows a detailed view of the lung's airways and air sacs in cross ...
[1] [2] These trials aimed to assess the efficacy and safety of ziritaxestat in patients with IPF, including those receiving standard of care treatment with pirfenidone or nintedanib. [1] However, both trials were prematurely terminated due to a lack of efficacy, as ziritaxestat failed to demonstrate significant improvement in lung function or ...
[1] [3] [6] But in most cases the cause is unknown (idiopathic pulmonary fibrosis). [1] [3] Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests. [1] No cure exists and treatment options are limited. [1] Treatment is directed toward improving symptoms and may include oxygen therapy and pulmonary rehabilitation.
Since the medical term for conditions of unknown cause is "idiopathic", the clinical term for UIP of unknown cause is idiopathic pulmonary fibrosis (IPF). [2] Examples of known causes of UIP include connective tissue diseases (primarily rheumatoid arthritis ), drug toxicity, chronic hypersensitivity pneumonitis , asbestosis and Hermansky ...
A new "20/20" episode, "File ‘M’ for Murder" airing Friday, Feb. 7, at 9 p.m. ET and streaming the next day on Hulu, examines the case. "Police quickly work to gather information about the ...
Patients with idiopathic pulmonary fibrosis were randomly assigned to treatment with oral pirfenidone or placebo for a minimum of 72 weeks. [47] In study 004, pirfenidone reduced decline in forced vital capacity. Mean change in FVC at week 72 was –8.0% in the pirfenidone 2403 mg/day group and –12.4% in the placebo group, a difference of 4.4%.
Treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy; and adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion with disease progression on or after prior ...
Ads
related to: nintedanib for ipf 1 8